全球仿製药市场 - 市场规模、份额、成长分析：按品牌、给药途径- 产业预测（2023-2030）

Global Generic Drugs Market Size, Share, Growth Analysis, By Brand (Pure and Branded), By Route(Administration, including oral) - Industry Forecast 2023-2030

出版日期: 2023年10月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球仿製药市场规模为4168.6亿美元，预计在预测期内（2023-2030年）年复合成长率为5.4%，从2022年的4393.7亿美元增长到6692亿美元2030年。

由于品牌药物专利到期、医疗成本上升以及对更便宜的治疗方案的需求等因素，全球仿製药市场正在经历显着增长。这种成长的关键驱动因素是许多重磅药物的专利已经到期，使得仿製药製造商能够竞争并以更低的价格提供基本药物。虽然慢性病的增加进一步增加了对具有成本效益的治疗方案的需求，但各国政府的政策和医疗保健倡议，特别是在新兴经济体，正在增加仿製药的可及性并降低医疗保健成本。我们的目标是减少这种情况。简化药物核准流程和法律规范的配合措施也正在推动市场扩张。然而，全球仿製药市场也面临挑战。

心血管疾病、糖尿病、呼吸系统疾病和癌症等慢性疾病在全球范围内的罹患率不断上升，刺激了对具有成本效益的治疗方案的需求，从而导致对仿製药市场的需求增加。

各国政府正在製定政策并发起倡议，以增加仿製药的使用，其总体目标是降低医疗保健成本、改善关键药物的获取以及促进仿製药的采用。这些策略涉及仿製药替代和价格法规机制。

仿製药行业面临着多方面且苛刻的法规环境，仿製药製造商必须通过复杂的核准流程，需要证明与品牌药的生物等效性。是的。这些法规障碍可能会阻碍仿製药进入市场并增加製造商的成本。

该报告考察了全球仿製药市场，并提供了市场概况，包括按品牌、给药途径、地区和参与市场的公司概况分類的趋势。

主要企业简介
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Mylan NV
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Dr. Reddy's Laboratories Ltd.
- Lupin Limited
- Cipla Limited
- Hikma Pharmaceuticals plc
- 雅阁医疗保健有限公司
- Aurobindo Pharma Limited
- Apotex Inc.
- Fresenius Kabi AG
- Zydus Cadila
- Glenmark Pharmaceuticals Ltd
- Torrent Pharmaceuticals Ltd.
- Amneal Pharmaceuticals, Inc.
- Bausch Health Companies Inc
- Alkem Laboratories Ltd.
- Aspen Pharmacare Holdings Limited

简介目录

Product Code: SQMIG35J2062

Global Generic Drugs Market size was valued at USD 416.86 Billion in 2021 and is poised to grow from USD 439.37 Billion in 2022 to USD 669.20 Billion by 2030, at a CAGR of 5.4% during the forecast period (2023-2030).

The global generic drugs market has seen remarkable growth due to factors like patent expirations of branded medications, rising healthcare expenses, and the need for more affordable treatment choices. This growth is primarily driven by the expiration of patents for many blockbuster drugs, enabling generic drug manufacturers to compete and offer lower-cost essential medications. The increasing prevalence of chronic diseases has further boosted the demand for cost-effective treatment options, while government policies and healthcare initiatives in various countries aim to enhance accessibility to generic drugs and reduce healthcare costs, particularly in emerging economies. Efforts to streamline drug approval processes and regulatory frameworks have also facilitated market expansion. However, the global generic drugs market encounters certain challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the global generic drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The global generic drugs market is segmented on the basis of brand, route, and region. By brand, the market is segmented into pure generic drugs and branded generic drugs. By route, the market is segmented into administration, including oral, topical, parental (injectable), and others (such as inhalation, nasal, and ophthalmic). By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers:

Increasing Chronic Diseases

The increasing worldwide incidence of chronic illnesses, including cardiovascular ailments, diabetes, respiratory issues, and cancer, is fueling the demand for cost-effective treatment options, leading to a rising market demand for generic drugs.

Government Initiatives

In numerous nations, governments are enacting policies and launching initiatives designed to encourage the utilization of generic medications, with the overarching goals of decreasing healthcare costs, enhancing access to vital drugs, and boosting generic drug adoption. These strategies involve mechanisms such as generic substitution and pricing regulations.

Restraints:

Complex Regulatory Environment

The generic drugs industry confronts a multifaceted and demanding regulatory environment, where generic drug producers must adeptly traverse intricate approval procedures that necessitate the demonstration of bioequivalence with branded medications. These regulatory hurdles have the potential to impede the market introduction of generic drugs and escalate expenses for manufacturers.

Perception and Trust Issues

Ensuring broader acceptance and adoption of generic drugs requires addressing the apprehensions of both patients and healthcare providers regarding the quality, effectiveness, and safety of generic medications when compared to their brand-name equivalents. To achieve this, it is imperative to establish trust and educate all stakeholders about the comparable quality and cost-effectiveness of generic drugs.

Market Trends:

Market consolidation in the pharmaceutical industry is on the rise, characterized by larger pharmaceutical companies either acquiring smaller generic drug manufacturers or forging strategic partnerships. This consolidation strategy is geared towards broadening product offerings, bolstering manufacturing capacities, and strengthening market presence.

There is a growing emphasis on biosimilars, generic versions of biologic drugs, as they gain momentum in both development and commercialization. These biosimilars are gaining significance in the worldwide generic drugs market by providing affordable alternatives to costly biologics.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Generic Drugs Market by Brand
- Market Overview
- Pure and Branded
Global Generic Drugs Market by Route
- Market Overview
- Administration
- including oral
- topical
- parental (injectable)
- and others (such as inhalation
- nasal
- and ophthalmic)
Global Generic Drugs Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Teva Pharmaceutical Industries Ltd. - Israel
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sandoz International GmbH (Novartis) - Switzerland
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mylan N.V. - Netherlands
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sun Pharmaceutical Industries Ltd. - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Dr. Reddy's Laboratories Ltd. - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Lupin Limited - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Cipla Limited - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Hikma Pharmaceuticals plc - UK
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Accord Healthcare Ltd. - UK
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Aurobindo Pharma Limited - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Apotex Inc. - Canada
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Fresenius Kabi AG - Germany
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Zydus Cadila - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Glenmark Pharmaceuticals Ltd. - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Torrent Pharmaceuticals Ltd. - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Amneal Pharmaceuticals, Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bausch Health Companies Inc. - Canada
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Alkem Laboratories Ltd. - India
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Aspen Pharmacare Holdings Limited - South Africa
Company Overview
Business Segment Overview
Financial Updates
Key Developments